Hutchmed (China) reported a 23% year-on-year increase in oncology revenue to $162 million for the first half of 2026, driven by robust product sales growth in China and expanding global demand for FRUZAQLA.

The company maintained its full-year revenue guidance of $330 million to $450 million, supported by a net income of $16 million and a cash reserve of $1.4 billion.

Financial Performance

Oncology revenue reached $162 million, comprising $121 million in product revenue. This represents a significant acceleration from the prior period, with China product sales growing over 40% led by Elunate and Sulanda. Ex-China sales of FRUZAQLA surged 70%, reflecting rapid geographic expansion outside the United States.

Total group revenue, including other ventures, amounted to $278 million. Research and development expenses rose to $79 million from $72 million in the same period last year, reflecting increased investment in clinical trials for AATTC assets and AI-driven discovery capabilities.

What the Numbers Show

The company’s profitability profile is heavily influenced by non-recurring items. While the current half-year net income stands at $16 million, management highlighted that the prior year included a $460 million gain from the divestment of SHPL and approximately $21 million in post-divestment share income. This divergence indicates that the current operational earnings are significantly lower than the headline figures of the previous year, despite the strong top-line growth in oncology products.

Commercial Updates

Elunate achieved 41% growth in the first half, maintaining its market leadership in second-line metastatic colorectal cancer. The recent National Reimbursement Drug List (NRDL) renewal included second-line mCRC indications, providing continued growth opportunities with flat pricing. Additionally, Elunate received approval for second-line renal cell carcinoma in May 2026, positioning it for potential NRDL inclusion later this year.

FRUZAQLA’s global expansion continues to drive momentum. Ex-US markets saw a 70% increase in sales, with Q2 growth accelerating to 27%. Management noted that reimbursement coverage in these new markets currently stands at only 50%, suggesting further upside as access improves. Takeda has confirmed fiscal year guidance of 25% growth for the asset.

Pipeline and Innovation

Hutchmed advanced its novel Antibody-Targeted Toxin Conjugate (ATTC) platform, initiating global Phase I trials for two first-in-class assets, A251 and A580. A third asset, HMPL-830, cleared its Investigational New Drug (IND) application and is expected to enter clinical trials in the second half of the year.

In hematology, sovleplenib’s NDAs for immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA) are under priority review. Phase III data presented at the European Hematology Association (EHA) conference showed a 66% durable response rate for wAIHA compared to 15% for placebo, highlighting significant efficacy advantages over standard care.

Savolitinib expanded its commercial footprint with a third-line gastric cancer approval, marking its fourth regulatory approval globally. Key Phase III studies, SAFFRON and CENOVO, are expected to provide data readouts in the second half of 2026, potentially opening major markets like the US and Europe for MET-driven lung cancer treatment.

HUTCHMED (China) Limited (Nasdaq/AIM: HCM; HKEX: 13) shares rose 17.94% to $13.60 on Thursday following the announcement of an exclusive development and license agreement with GSK plc (GSK) for its first-in-class KRAS-EGFR antibody-targeted therapy conjugate, HMPL-A830.

The deal grants GSK worldwide rights to develop and commercialize the drug candidate, excluding Mainland China, Hong Kong, Macau, and Taiwan. Clinical development will initially focus on colorectal, pancreatic, and lung cancer indications.

Deal Terms

Under the agreement, HUTCHMED will receive a US$110 million upfront payment at closing. This is subject to customary closing conditions, including the completion of antitrust regulatory reviews.

The total potential value of the transaction is US$1.295 billion. This figure includes the upfront payment plus potential development, regulatory, and commercial milestone payments totaling up to US$1.185 billion. Additionally, GSK’s subsidiary will pay tiered royalties on annual net sales.

HUTCHMED retains full development and commercialization rights in Mainland China, Hong Kong, Macau, and Taiwan. The company will also be responsible for the global Phase I development program, expected to start in the second half of 2026 (clinicaltrials.gov identifier NCT07718581). The contract also grants GSK first negotiation rights for an earlier-stage ATTC drug candidate.

What the Numbers Show

The licensing structure highlights a significant divergence in immediate versus long-term revenue potential. While the upfront payment of US$110 million provides immediate liquidity, the vast majority of the deal’s potential value—US$1.185 billion, or approximately 91% of the total potential consideration—is contingent on future development, regulatory, and commercial milestones. This indicates that HUTCHMED’s long-term financial upside from this asset is heavily dependent on HMPL-A830 successfully progressing through clinical trials and achieving market approval globally.

Asset Profile

HMPL-A830 is an Antibody-Targeted Therapy Conjugate (ATTC). It comprises a highly selective Kirsten rat sarcoma (KRAS) small molecule inhibitor payload conjugated to an anti-epidermal growth factor receptor (EGFR) antibody.

An ATTC enables tumor-selective activity of potent, cell-killing payloads by leveraging antibody-guided therapy. The drug is designed to address unmet medical needs in patients with KRAS-altered tumors, which have high incidence rates in colorectal, lung, and pancreatic cancers. By delivering the KRAS inhibitor directly to EGFR-expressing tumors while simultaneously blocking EGFR signaling, the therapy aims to enhance efficacy, durability, and tolerability compared to current standards of care.

GSK’s subsidiary will handle all subsequent clinical development and commercialization activities outside the Greater China region. BofA Securities acted as the exclusive financial advisor to HUTCHMED.